Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2(+) breast cancer in the adaptively randomized I-SPY2 trial

HER2-targeted therapy dramatically improves outcomes in early breast cancer. Here we report the results of two HER2-targeted combinations in the neoadjuvant I-SPY2 phase 2 adaptive platform trial for early breast cancer at high risk of recurrence: ado-trastuzumab emtansine plus pertuzumab (T-DM1/P)...

Descripción completa

Detalles Bibliográficos
Autores principales: Clark, Amy S., Yau, Christina, Wolf, Denise M., Petricoin, Emanuel F., van ‘t Veer, Laura J., Yee, Douglas, Moulder, Stacy L., Wallace, Anne M., Chien, A. Jo, Isaacs, Claudine, Boughey, Judy C., Albain, Kathy S., Kemmer, Kathleen, Haley, Barbara B., Han, Hyo S., Forero-Torres, Andres, Elias, Anthony, Lang, Julie E., Ellis, Erin D., Yung, Rachel, Tripathy, Debu, Nanda, Rita, Wulfkuhle, Julia D., Brown-Swigart, Lamorna, Gallagher, Rosa I., Helsten, Teresa, Roesch, Erin, Ewing, Cheryl A., Alvarado, Michael, Crane, Erin P., Buxton, Meredith, Clennell, Julia L., Paoloni, Melissa, Asare, Smita M., Wilson, Amy, Hirst, Gillian L., Singhrao, Ruby, Steeg, Katherine, Asare, Adam, Matthews, Jeffrey B., Berry, Scott, Sanil, Ashish, Melisko, Michelle, Perlmutter, Jane, Rugo, Hope S., Schwab, Richard B., Symmans, W. Fraser, Hylton, Nola M., Berry, Donald A., Esserman, Laura J., DeMichele, Angela M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571284/
https://www.ncbi.nlm.nih.gov/pubmed/34741023
http://dx.doi.org/10.1038/s41467-021-26019-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571284/
https://www.ncbi.nlm.nih.gov/pubmed/34741023
http://dx.doi.org/10.1038/s41467-021-26019-y

Ejemplares similares